[The study in resveratrol function to acute lung injury sourced from severe acute pancreatitis].
OBJECTIVE
To study the effect of resveratrol to the onset and progress of acute lung injury in rat model of severe acute pancreatitis (SAP).


METHODS
The SAP model was made by injecting 4% sodium taurocholate, a dosage of 0.1 mL/100 g, into the biliopancreatic duct. The control group is formed by injecting the equal amount of N. S into the biliopancreatic duct. For treatment group, after induction of the SAP model, the resveratrol was used to injection at a dosage of 0.3 mL/100 g through the penis vein; at solvent group, after induction of the SAP model, injecting the same amount of tween 80 through the penis vein. All rats were sacrificed at 3, 6, 12 hours. The injuries of lung were checked by pulmonary morphology change, the change of protein in bronchi alveolar lung fluid (BALF). The changes of iNOS were analyzed with special method. PECAM-1, TGF-beta1 was also detected by immunohistochemistry.


RESULTS
For pulmonary morphology change, there were more inflammation cells, more pulmonary edema in experimental group than in treatment group. And in experimental group, with the postponement, the amount of iNOS is increasing (P < 0.05). However, in treatment group, the amout of iNOS was significantly less than in experimental group. The same case was that PECAM-1 and TGF-beta1 of experimental group were higher expression than that of treatment group (P < 0.05).


CONCLUSIONS
Resveratrol can inhibit the expression of iNOS, PECAM-1, TGF-beta1, and reduce the adhesion between inflammatory cells and endothelium cells, so it may reduce the severity of acute lung injury complicated with severe acute pancreatitis.
Wang
Zheng
Z
Department of Hepatobillary Surgery, First Affiliated Hospital of Medical College of Xi'an Jiaotong University, Xi'an 710061, China.
Ma
Oing-Yong
OY
Ren
Lei
L
Li
Zhen-Dong
ZD
Li
Li
L
D055371:Acute Lung Injury / Q000188:drug therapy* / Q000209:etiology* / Q000378:metabolism / Q000473:pathology; D000818:Animals; D001992:Bronchoalveolar Lavage Fluid; D018450:Disease Progression; D005786:Gene Expression Regulation / Q000187:drug effects; D008168:Lung / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D008297:Male; D052247:Nitric Oxide Synthase Type II / Q000378:metabolism; D010195:Pancreatitis / Q000150:complications*; D019408:Platelet Endothelial Cell Adhesion Molecule-1 / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D000077185:Resveratrol; D013267:Stilbenes / Q000494:pharmacology* / Q000627:therapeutic use; D053773:Transforming Growth Factor beta1 / Q000378:metabolism
D019408:Platelet Endothelial Cell Adhesion Molecule-1; D013267:Stilbenes; D053773:Transforming Growth Factor beta1; D052247:Nitric Oxide Synthase Type II; D000077185:Resveratrol